vs
Digimarc CORP（DMRC）与Lineage Cell Therapeutics, Inc.（LCTX）财务数据对比。点击上方公司名可切换其他公司
Digimarc CORP的季度营收约是Lineage Cell Therapeutics, Inc.的1.3倍（$8.9M vs $6.6M），Lineage Cell Therapeutics, Inc.净利率更高（12.9% vs -47.2%，领先60.1%），Lineage Cell Therapeutics, Inc.同比增速更快（130.4% vs 2.9%），Digimarc CORP自由现金流更多（$895.0K vs $-5.3M），过去两年Lineage Cell Therapeutics, Inc.的营收复合增速更高（113.9% vs -5.3%）
迪吉马克公司是一家企业软件与服务提供商，其主打产品包含带数字标识符的软件，主要用于解决防伪问题、验证产品真伪、提升回收准确性以及实现供应链可追溯，产品可广泛应用于服装、快消品、美妆健康、汽车等多个行业领域。
谱系细胞治疗公司是一家处于临床阶段的生物科技企业，专注于开发满足未竟医疗需求的新型细胞疗法。其研发项目依托自主成熟的细胞疗法专有平台，以及内部配套的研发与生产能力，可利用多能细胞和祖细胞原料，开发制造专业化的终末分化人类细胞，推进对应疗法落地。
DMRC vs LCTX — 直观对比
营收规模更大
DMRC
是对方的1.3倍
$6.6M
营收增速更快
LCTX
高出127.5%
2.9%
净利率更高
LCTX
高出60.1%
-47.2%
自由现金流更多
DMRC
多$6.2M
$-5.3M
两年增速更快
LCTX
近两年复合增速
-5.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $8.9M | $6.6M |
| 净利润 | $-4.2M | $851.0K |
| 毛利率 | 63.5% | — |
| 营业利润率 | -48.2% | -99.1% |
| 净利率 | -47.2% | 12.9% |
| 营收同比 | 2.9% | 130.4% |
| 净利润同比 | 51.4% | 126.0% |
| 每股收益（稀释后） | $-0.18 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DMRCLCTX
| Q4 25 | $8.9M | $6.6M | ||
| Q3 25 | $7.6M | $3.7M | ||
| Q2 25 | $8.0M | $2.8M | ||
| Q1 25 | $9.4M | $1.5M | ||
| Q4 24 | $8.7M | $2.9M | ||
| Q3 24 | $9.4M | $3.8M | ||
| Q2 24 | $10.4M | $1.4M | ||
| Q1 24 | $9.9M | $1.4M |
净利润DMRCLCTX
| Q4 25 | $-4.2M | $851.0K | ||
| Q3 25 | $-8.2M | $-29.8M | ||
| Q2 25 | $-8.2M | $-30.5M | ||
| Q1 25 | $-11.7M | $-4.1M | ||
| Q4 24 | $-8.6M | $-3.3M | ||
| Q3 24 | $-10.8M | $-3.0M | ||
| Q2 24 | $-9.3M | $-5.8M | ||
| Q1 24 | $-10.3M | $-6.5M |
毛利率DMRCLCTX
| Q4 25 | 63.5% | — | ||
| Q3 25 | 58.3% | — | ||
| Q2 25 | 58.8% | — | ||
| Q1 25 | 65.0% | 97.6% | ||
| Q4 24 | 60.8% | 94.6% | ||
| Q3 24 | 62.4% | 99.0% | ||
| Q2 24 | 66.1% | 96.9% | ||
| Q1 24 | 62.5% | 93.2% |
营业利润率DMRCLCTX
| Q4 25 | -48.2% | -99.1% | ||
| Q3 25 | -109.7% | -102.9% | ||
| Q2 25 | -105.2% | -715.4% | ||
| Q1 25 | -128.9% | -433.1% | ||
| Q4 24 | -105.1% | -178.2% | ||
| Q3 24 | -120.4% | -101.6% | ||
| Q2 24 | -96.2% | -416.7% | ||
| Q1 24 | -109.2% | -461.3% |
净利率DMRCLCTX
| Q4 25 | -47.2% | 12.9% | ||
| Q3 25 | -106.9% | -809.0% | ||
| Q2 25 | -102.6% | -1101.8% | ||
| Q1 25 | -125.2% | -275.6% | ||
| Q4 24 | -99.9% | -114.1% | ||
| Q3 24 | -113.9% | -80.3% | ||
| Q2 24 | -89.3% | -409.1% | ||
| Q1 24 | -104.0% | -453.0% |
每股收益（稀释后）DMRCLCTX
| Q4 25 | $-0.18 | $0.00 | ||
| Q3 25 | $-0.38 | $-0.13 | ||
| Q2 25 | $-0.38 | $-0.13 | ||
| Q1 25 | $-0.55 | $-0.02 | ||
| Q4 24 | $-0.40 | $0.00 | ||
| Q3 24 | $-0.50 | $-0.02 | ||
| Q2 24 | $-0.43 | $-0.03 | ||
| Q1 24 | $-0.50 | $-0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.9M | $55.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $40.2M | $44.5M |
| 总资产 | $53.0M | $112.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DMRCLCTX
| Q4 25 | $12.9M | $55.8M | ||
| Q3 25 | $12.6M | $40.5M | ||
| Q2 25 | $16.1M | $42.3M | ||
| Q1 25 | $21.6M | $47.9M | ||
| Q4 24 | $28.7M | $47.8M | ||
| Q3 24 | $33.7M | $32.7M | ||
| Q2 24 | $41.5M | $38.5M | ||
| Q1 24 | $48.9M | $43.6M |
股东权益DMRCLCTX
| Q4 25 | $40.2M | $44.5M | ||
| Q3 25 | $41.4M | $22.0M | ||
| Q2 25 | $46.5M | $48.4M | ||
| Q1 25 | $50.0M | $79.0M | ||
| Q4 24 | $61.4M | $78.4M | ||
| Q3 24 | $70.2M | $66.2M | ||
| Q2 24 | $77.2M | $68.3M | ||
| Q1 24 | $84.5M | $72.4M |
总资产DMRCLCTX
| Q4 25 | $53.0M | $112.6M | ||
| Q3 25 | $55.4M | $89.6M | ||
| Q2 25 | $60.7M | $90.8M | ||
| Q1 25 | $66.5M | $111.8M | ||
| Q4 24 | $75.8M | $113.2M | ||
| Q3 24 | $85.0M | $96.6M | ||
| Q2 24 | $93.4M | $102.8M | ||
| Q1 24 | $99.7M | $108.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $991.0K | $-4.9M |
| 自由现金流经营现金流 - 资本支出 | $895.0K | $-5.3M |
| 自由现金流率自由现金流/营收 | 10.0% | -79.9% |
| 资本支出强度资本支出/营收 | 1.1% | 6.0% |
| 现金转化率经营现金流/净利润 | — | -5.73× |
| 过去12个月自由现金流最近4个季度 | $-12.3M | $-19.4M |
8季度趋势，按日历期对齐
经营现金流DMRCLCTX
| Q4 25 | $991.0K | $-4.9M | ||
| Q3 25 | $-2.6M | $-3.6M | ||
| Q2 25 | $-4.7M | $-5.5M | ||
| Q1 25 | $-5.5M | $-4.9M | ||
| Q4 24 | $-4.2M | $-6.3M | ||
| Q3 24 | $-7.1M | $-5.8M | ||
| Q2 24 | $-6.8M | $-5.2M | ||
| Q1 24 | $-8.4M | $-5.8M |
自由现金流DMRCLCTX
| Q4 25 | $895.0K | $-5.3M | ||
| Q3 25 | $-2.8M | $-3.6M | ||
| Q2 25 | $-4.9M | $-5.6M | ||
| Q1 25 | $-5.5M | $-5.0M | ||
| Q4 24 | $-4.2M | $-6.7M | ||
| Q3 24 | $-7.2M | $-5.9M | ||
| Q2 24 | $-6.9M | $-5.2M | ||
| Q1 24 | $-8.5M | $-5.8M |
自由现金流率DMRCLCTX
| Q4 25 | 10.0% | -79.9% | ||
| Q3 25 | -36.9% | -98.6% | ||
| Q2 25 | -61.0% | -200.8% | ||
| Q1 25 | -59.1% | -331.8% | ||
| Q4 24 | -49.1% | -234.0% | ||
| Q3 24 | -75.7% | -156.1% | ||
| Q2 24 | -66.1% | -371.2% | ||
| Q1 24 | -85.8% | -403.1% |
资本支出强度DMRCLCTX
| Q4 25 | 1.1% | 6.0% | ||
| Q3 25 | 2.9% | 0.3% | ||
| Q2 25 | 2.5% | 0.5% | ||
| Q1 25 | 0.6% | 6.5% | ||
| Q4 24 | 0.2% | 12.7% | ||
| Q3 24 | 0.7% | 3.0% | ||
| Q2 24 | 0.3% | 3.6% | ||
| Q1 24 | 1.1% | 2.6% |
现金转化率DMRCLCTX
| Q4 25 | — | -5.73× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DMRC
| Subscription | $5.3M | 60% |
| The Government | $3.6M | 41% |
LCTX
| Collaboration Revenues | $6.3M | 95% |
| Other | $345.0K | 5% |
